132 related articles for article (PubMed ID: 32860360)
1. Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy.
Crutchley RD; Jacobs DM; Gathe J; Mayberry C; Bulayeva N; Rosenblatt KP; Garey KW
Curr HIV Res; 2021; 19(1):61-72. PubMed ID: 32860360
[TBL] [Abstract][Full Text] [Related]
2. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
3. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
[TBL] [Abstract][Full Text] [Related]
5. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
6. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
Cooper C; la Porte C; Tossonian H; Sampalis J; Ackad N; Conway B
HIV Clin Trials; 2012; 13(4):179-88. PubMed ID: 22849960
[TBL] [Abstract][Full Text] [Related]
7. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM
AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590
[TBL] [Abstract][Full Text] [Related]
8. Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.
Tran TA; Ghosn J; Avettand-Fenoël V; Hendel-Chavez H; de Goër de Herve MG; Cohen-Codar I; Rouzioux C; Delfraissy JF; Taoufik Y
J Antimicrob Chemother; 2015 Sep; 70(9):2627-31. PubMed ID: 26023212
[TBL] [Abstract][Full Text] [Related]
9. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
10. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
11. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
Matoga MM; Hosseinipour MC; Aga E; Ribaudo HJ; Kumarasamy N; Bartlett J; Hughes MD;
Antivir Ther; 2017; 22(3):205-213. PubMed ID: 27740537
[TBL] [Abstract][Full Text] [Related]
12. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
13. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Santos JR; Llibre JM; Berrio-Galan D; Bravo I; Miranda C; Pérez-Alvarez S; Pérez-Alvarez N; Paredes R; Clotet B; Moltó J
J Antimicrob Chemother; 2015 Apr; 70(4):1124-9. PubMed ID: 25525196
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
Arribas JR; Pulido F; Delgado R; Lorenzo A; Miralles P; Arranz A; González-García JJ; Cepeda C; Hervás R; Paño JR; Gaya F; Carcas A; Montes ML; Costa JR; Peña JM
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):280-7. PubMed ID: 16249701
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
[TBL] [Abstract][Full Text] [Related]
19. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
20. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
